Literature DB >> 12552569

NF1 gene analysis based on DHPLC.

Alessandro De Luca1, Anna Buccino, Debora Gianni, Massimo Mangino, Sandra Giustini, Antonio Richetta, Luigina Divona, Stefano Calvieri, Rita Mingarelli, Bruno Dallapiccola.   

Abstract

The high mutation rate at the NF1 locus results in a wide range of molecular abnormalities. The majority of these mutations are private and rare, generating elevated allelic diversity with a restricted number of recurrent mutations. In this study, we have assessed the efficacy of denaturing high-performance liquid chromatography (DHPLC), for detecting mutation in the NF1 gene. DHPLC is a fast and highly sensitive technique based on the detection of heteroduplexes in PCR products by ion pair reverse-phase HPLC under partially denaturing conditions. We established theoretical conditions for DHPLC analysis of all coding exons and splice junctions of the NF1 gene using the WAVEmaker software version 4.1.40 and screened for mutations a panel of 40 unrelated NF1 patients (25 sporadic and 15 familial), genetically uncharacterized. Disruptive mutations were identified in 29 individuals with an overall mutation detection rate of 72.5%. The mutations included eight deletions (exons 4b, 7, 10a, 14, 26, and 31), one insertion (exon 8), nine nonsense mutation (exons 10a, 13, 23.1, 27a, 29, 31, and 36), six missense mutations (exons 15, 16, 17, 24, and 31), four splice errors (exons 11, 14, 36, and 40) and a complex rearrangement within exon 16. Eighteen (62%) of the identified disruptive mutations are novel. Seven unclassified and three previously reported polymorphisms were also detected. None of the missense mutations identified in this study were found after screening of 150 controls. Our results suggest that DHPLC provides an accurate method for the rapid identification of NF1 mutations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552569     DOI: 10.1002/humu.9111

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

1.  Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.

Authors:  I Torrente; F Arturi; L D'Aloiso; A Colosimo; A De Luca; E Ferretti; D Russo; E Chiefari; D Scarpelli; M Bisceglia; B Dallapiccola; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 2.  Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions.

Authors:  Klaus Scheffzek; Giridhar Shivalingaiah
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

3.  A highly sensitive genetic protocol to detect NF1 mutations.

Authors:  María Carmen Valero; Yolanda Martín; Elisabete Hernández-Imaz; Alba Marina Hernández; Germán Meleán; Ana María Valero; Francisco Javier Rodríguez-Álvarez; Dolores Tellería; Concepción Hernández-Chico
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

4.  Functional analysis of splicing mutations in exon 7 of NF1 gene.

Authors:  Irene Bottillo; Alessandro De Luca; Annalisa Schirinzi; Valentina Guida; Isabella Torrente; Stefano Calvieri; Cristina Gervasini; Lidia Larizza; Antonio Pizzuti; Bruno Dallapiccola
Journal:  BMC Med Genet       Date:  2007-02-12       Impact factor: 2.103

5.  Identification of type A, B, E, and F botulinum neurotoxin genes and of botulinum neurotoxigenic clostridia by denaturing high-performance liquid chromatography.

Authors:  Giovanna Franciosa; Manoocheher Pourshaban; Alessandro De Luca; Anna Buccino; Bruno Dallapiccola; Paolo Aureli
Journal:  Appl Environ Microbiol       Date:  2004-07       Impact factor: 4.792

6.  RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.

Authors:  Terje Ahlquist; Irene Bottillo; Stine A Danielsen; Gunn I Meling; Torleiv O Rognum; Guro E Lind; Bruno Dallapiccola; Ragnhild A Lothe
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

7.  Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: A case report.

Authors:  Giovanni Ponti; Giovanni Pellacani; Davide Martorana; Victor Desmond Mandel; Pietro Loschi; Annamaria Pollio; Annarita Pecchi; Cristina Dealis; Stefania Seidenari; Aldo Tomasi
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

8.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification.

Authors:  A De Luca; I Bottillo; M C Dasdia; A Morella; V Lanari; L Bernardini; L Divona; S Giustini; L Sinibaldi; A Novelli; I Torrente; A Schirinzi; B Dallapiccola
Journal:  J Med Genet       Date:  2007-12       Impact factor: 6.318

9.  NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.

Authors:  Alessandro De Luca; Irene Bottillo; Anna Sarkozy; Claudio Carta; Cinzia Neri; Emanuele Bellacchio; Annalisa Schirinzi; Emanuela Conti; Giuseppe Zampino; Agatino Battaglia; Silvia Majore; Maria M Rinaldi; Massimo Carella; Bruno Marino; Antonio Pizzuti; Maria Cristina Digilio; Marco Tartaglia; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2005-10-26       Impact factor: 11.025

10.  p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas.

Authors:  Valentina Pinna; Valentina Lanari; Paola Daniele; Federica Consoli; Emanuele Agolini; Katia Margiotti; Irene Bottillo; Isabella Torrente; Alessandro Bruselles; Caterina Fusilli; Anna Ficcadenti; Sara Bargiacchi; Eva Trevisson; Monica Forzan; Sandra Giustini; Chiara Leoni; Giuseppe Zampino; Maria Cristina Digilio; Bruno Dallapiccola; Maurizio Clementi; Marco Tartaglia; Alessandro De Luca
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.